Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 5, 1997, Pages 484-489

  Park, Joon Oh ^a   Chung, Hyun Cheol ^a   Cho, Jae Yong ^b   Sun Rha, Young ^b   You, Nae Choon ^b   Kim, Joo Hang ^a   Noh, Sung Hoon ^a   Kim, Choong Bai ^b   Min, Jin Sik ^a   Kim, Byung Soo ^a   Roh, Jae Kyung ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Advanced gastric cancer; mFAM chemotherapy; Palliative surgery

Indexed keywords

DOXORUBICIN; FLUOROURACIL; MITOMYCIN C;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GASTRECTOMY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PROGNOSIS; STOMACH BYPASS; STOMACH CANCER; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MITOMYCIN; PALLIATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 0343923729     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199710000-00010     Document Type: Article

References (30)

1. Ministry of Health and Social Affairs, Republic of Korea. 5 years' report for cancer registry program in Republic of Korea (1982.7.1-1987.6.30). J Korean Cancer Assoc 1989:21:151216.
2. Kim IS. Cause of death in Korean peoples. J Korean Med Assoc 1993:36:271-84.
3. Wilke H, Preusser P, Fink U, et al. New developments in the treatment of gastric cancer. Semin Oiicol 1990; 17:61-70.
4. Moertel CG. The natural history of advanced gastric cancer. Surg Gynecol Obstet 1986; 126:1971-4.
5. Findlay M, Cunningham D. Chemotherapy of carcinoma of the stomach. Cancer Treat Rev 1993; 19:29-44.
6. MacDonald JS, Woolley PV, Smythe T, et al. 5-fluorouracil, adriamycin and mitomycin-C(FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 1979;44: 42-7.
7. MacDonald JS, Schein PS, Woolley PV, et al. 5-fluorouraciI, doxorubicin and mitomycin-C(FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980;93:5339.
8. Moertel CG, Rubin J, O'Connell MJ, et al. A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinoma. J Clin Oncol 1986;4:1053-7.
9. Kim NK, Park YS, Heo DS, et al. A phase III randomized study of 5-fluorouracil and cisplatin vs 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-8.
10. Ajani JA, Ota DM, Jackson DE. Current strategies in the management of local, regional and metastatic gastric carcinoma. Cancer 1991;67:260-5.
11. Preusser P, Wilke H, Achterrath W, et al. Phase III study with the combination of etoposide, doxorubicin and cisplatin in advanced gastric cancer. J Clin Oncol 1989; 7:1310-7.
12. Douglass JHO, Lavin PT, Goudsmit A, et al. An Eastern Cooperative Oncology Group evaluation of combination of methylCCNU, mitomycin, adriamycin, and 5-fluorouracil in advanced measurable gastric cancer. J Clin Oncol 1984;2(12):I372-81.
13. Gohmann JJ, MacDonald JS. Chemotherapy of gastric cancer. Cancer Invest 1989; 7:39-52.
14. Cullian S, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic cancer and gastric cancer. JAMA 1985;253:2061-7.
15. Sotos GA, Grogan L, Allegra CJ. Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev 1994;20: 11-49.
16. Carlson RW, Sikic BI. Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med 1983;99:823-33.
17. Seifert P, Baker L, Reed M. Comparison of continuous infused 5-fluorouracil with bolus injection in the treatment of patients with colorectal adenocarcinoma. Cancer 1975;36:123-8.
18. Moynihan T, Hansen R, Anderson T, et al. Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol 1988;4:685-96.
19. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981:47:207-14.
20. Thompson GB, Heerden JA, Michael GS. Adenocarcinoma of the stomach: are we making progress? Lancet 1993:342:7138.
21. Wanebo HJ, Kennedy BJ, ChmielJ, et al. Cancer of the stomach: a patient care study by American college of surgeons. Ann Surg 1993:218:583-92.
22. Lawrence W Jr, McNeer G. The effectiveness of surgery for palliation of incurable gastric cancer. Cancer 1958;! 1:28-32.
23. Hallissey MT, Allum WH, Roginski C, et al. Palliative surgery for gastric cancer. Cancer 1988;62:440-4.
24. Maehara Y, Kakeji Y, Takahahashi I, et al. Noncurative resection for advanced gastric cancer. J Surg Oncol 1992; 51:2215.
25. MacDonald JS, Gohmann JJ. Chemotherapy of advanced gastric cancer: present status, future prospects. Semin Oncol 1988; 15(suppl 4):42-9.
26. Saini A, Waxman J. Chemotherapy for gastric cancer. Gut 1992;33:1153-4.
27. Coombes RC, Schein PS, Chilvers CED, et al. Randomized trial comparing adjuvant 5-fluorouracil and doxorubicin, and mitomycin-C with no treatment in operable gastric cancer. J Clin Oncol 1990:8:1362-9.
28. Cunningham D, Hole D, Taggart DJ, et al. Evaluation of the prognostic factors in gastric cancer: the effect of chemotherapy on survival. Br J Surg 1987;74:715-20.
29. Lavin PT, Bruckner H\V, Plaxe SC. Studies in prognostic factors relating to chemotherapy for advanced gastric cancer. Cancer 1982;50:2016-23.
30. Maehara Y, Takahashi I, Yoshida M, et al. Postgastrectomy anticancer chemotherapy for stage IV gastric cancer equally tolerable for patient under and over 65. Anticancer Res 1993; 13:27-39.